![Axel Gaston Glasmacher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Axel Gaston Glasmacher
Director/Board Member at
RYVU THERAPEUTICS S.A.
Profile
Axel Gaston Glasmacher is currently Independent Director at Active Biotech AB since 2020, Treasurer & Director at The Cancer Drug Development Forum, General Director at AG Life Science Consulting Gmbh & Co. Kg since 2018, General Director at Glasmacher Verwaltungs GmbH, Director at AvenCell Therapeutics, Inc. since 2021, and Member-Supervisory Board at Ryvu Therapeutics SA since 2019.
Former roles include Non-Executive Chairman at 4D Pharma Plc from 2020 to 2023 and Senior VP-Global Clinical Research & Development at Celgene Corp.
from 2016 to 2018.
Education was completed at the University of Bonn with undergraduate and doctorate degrees.
Axel Gaston Glasmacher active positions
| Companies | Position | Start |
|---|---|---|
| RYVU THERAPEUTICS S.A. | Director/Board Member | 01/10/2019 |
| ACTIVE BIOTECH AB | Director/Board Member | 01/01/2020 |
The Cancer Drug Development Forum
 The Cancer Drug Development Forum The Cancer Drug Development Forum (CDDF) is a neutral, non-competitive multi-stakeholder platform dedicated to accelerating the development and delivery of effective cancer therapies. The private company is based in Woluwe-Saint-Lambert, Belgium. It brings together patients, academia, pharmaceutical industry members, regulatory agencies, health technology assessment bodies, and patient advocacy groups to foster collaboration, open dialogue, and knowledge sharing in oncology drug development. CDDF organizes conferences, workshops, and webinars on topics such as artificial intelligence in clinical trials, development strategies, patient access, diversity, immuno-oncology, real-world data, and pediatric cancer outcomes. The forum leads initiatives like Accelerating Clinical Trials in the EU (ACT EU) and a diversity initiative to improve clinical trial design and representativeness in research. It publishes white papers, executive summaries, reports, and guidance documents to address challenges and propose solutions for advancing cancer drug development. | Director/Board Member | - |
AG Life Science Consulting Gmbh & Co. Kg | Chief Executive Officer | - |
Glasmacher Verwaltungs GmbH | Chief Executive Officer | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for treatment of cancers | Director/Board Member | 01/07/2021 |
Former positions of Axel Gaston Glasmacher
| Companies | Position | End |
|---|---|---|
| 4D PHARMA PLC | Chairman | 15/03/2023 |
| CELGENE | Chief Tech/Sci/R&D Officer | 01/02/2018 |
Training of Axel Gaston Glasmacher
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
59
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Active Biotech AB
 Active Biotech AB BiotechnologyHealth Technology Develops drugs for cancer, neurodegenerative and inflammatory diseases | Health Technology |
University of Bonn
 University of Bonn Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ryvu Therapeutics SA
 Ryvu Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops and sells therapies for precision oncology | Health Technology |
4D Pharma Plc
 4D Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which engages in the development of live bio therapeutics | Health Technology |
The Cancer Drug Development Forum
The Cancer Drug Development Forum The Cancer Drug Development Forum (CDDF) is a neutral, non-competitive multi-stakeholder platform dedicated to accelerating the development and delivery of effective cancer therapies. The private company is based in Woluwe-Saint-Lambert, Belgium. It brings together patients, academia, pharmaceutical industry members, regulatory agencies, health technology assessment bodies, and patient advocacy groups to foster collaboration, open dialogue, and knowledge sharing in oncology drug development. CDDF organizes conferences, workshops, and webinars on topics such as artificial intelligence in clinical trials, development strategies, patient access, diversity, immuno-oncology, real-world data, and pediatric cancer outcomes. The forum leads initiatives like Accelerating Clinical Trials in the EU (ACT EU) and a diversity initiative to improve clinical trial design and representativeness in research. It publishes white papers, executive summaries, reports, and guidance documents to address challenges and propose solutions for advancing cancer drug development. | |
AG Life Science Consulting Gmbh & Co. Kg | |
Glasmacher Verwaltungs GmbH | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for treatment of cancers | Health Technology |
- Stock Market
- Insiders
- Axel Gaston Glasmacher
